Vinh-Hung Vincent, Everaert Hendrik, Farid Karim, Djassemi Navid, Baudin-Veronique Jacqueline, Bougas Stefanos, Michailovich Yuriy, Joachim-Contaret Clarisse, Cécilia-Joseph Elsa, Verschraegen Claire, Nguyen Nam P
Vincent Vinh-Hung, Stefanos Bougas, Department of Radiation Oncology, University Hospital of Martinique, Fort-de-France 97200, Martinique.
World J Radiol. 2017 Jul 28;9(7):312-320. doi: 10.4329/wjr.v9.i7.312.
To investigate rates of distant metastases (DM) detected with [18]fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in early stage invasive breast cancer.
We searched the English language literature databases of PubMed, EMBASE, ISI Web of Knowledge, Web of Science and Google Scholar, for publications on DM detected in patients who had FDG-PET/CT scans as part of the staging for early stages of breast cancer (stage I and II), prior to or immediately following surgery. Reports published between 2011 and 2017 were considered. The systematic review was conducted according to the PRISMA guidelines.
Among the 18 total studies included in the analysis, the risk of DM ranged from 0% to 8.3% and 0% to 12.9% for stage I and II invasive breast cancer, respectively. Among the patients with clinical stage II, the rate of occult metastases diagnosed by FDG-PET/CT was 7.2% (range, 0%-19.6%) for stage IIA and 15.8% (range, 0%-40.8%) for stage IIB. In young patients (< 40-year-old), FDG-PET/CT demonstrated a higher prevalence of DM at the time of diagnosis for those with aggressive histology (., triple-negative receptors and poorly differentiated grade).
Young patients with poorly differentiated tumors and stage IIB triple-negative breast cancer may benefit from FDG-PET/CT at initial staging to detect occult DM prior to surgery.
研究[18]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）检测早期浸润性乳腺癌远处转移（DM）的发生率。
我们检索了PubMed、EMBASE、ISI Web of Knowledge、Web of Science和谷歌学术等英文文献数据库，查找有关在乳腺癌早期（I期和II期）分期过程中，手术前或手术后立即进行FDG-PET/CT扫描的患者中检测到DM的出版物。考虑2011年至2017年发表的报告。根据PRISMA指南进行系统评价。
在纳入分析的18项研究中，I期和II期浸润性乳腺癌的DM风险分别为0%至8.3%和0%至12.9%。在临床II期患者中，FDG-PET/CT诊断的隐匿性转移率在IIA期为7.2%（范围0%-19.6%），在IIB期为15.8%（范围0%-40.8%）。在年轻患者（<40岁）中，FDG-PET/CT显示侵袭性组织学类型（如三阴性受体和低分化分级）患者在诊断时DM的患病率较高。
低分化肿瘤的年轻患者和IIB期三阴性乳腺癌患者在初始分期时可能受益于FDG-PET/CT，以在手术前检测隐匿性DM。
